AEON BIOPHARMA INC

AEON Biopharma insider buying sparks optimism: Timothy Lynch’s 1.15 m shares at $0.21 reveal confidence amid a crypto‑payment partnership and potential neurotoxin breakthrough.

Insider buying of AEON Biopharma’s stock signals confidence in its promising neurotoxin pipeline and early‑stage safety data, offering insight for investors and clinicians.

AEON Biopharma CEO’s 3 M RSU grant signals confidence in the company’s oncology pipeline, linking executive pay to Phase III results and regulatory approvals.